"Promising Results Propel Moderna's Combined Covid and Flu Vaccine to Final Trial Stage"

Moderna's combination vaccine targeting Covid and the flu, mRNA-1083, has shown positive results in an early to mid-stage study and will move to a final stage trial in adults aged 50 and above this year. The vaccine generated a strong immune response similar to or greater than currently available flu vaccines and Moderna's bivalent Covid vaccine. The company believes combination vaccines will simplify protection against respiratory viruses and hopes to win regulatory approval by 2025. Moderna is also developing a combination shot targeting the flu and RSV, as well as a vaccine targeting all three respiratory viruses: Covid, flu, and RSV. Pfizer and BioNTech are also developing a vaccine targeting both Covid and the flu, with a phase one trial underway and expected launch in 2024 or later.